PRODUCT MONOGRAPH

PrTEVA-CLONIDINE
(clonidine hydrochloride)
USP
TABLETS
0.025 mg

VASCULAR STABILIZER FOR THE TREATMENT OF MENOPAUSAL FLUSHING

Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9

Date of Revision:
February 6, 2014

Submission Control No: 170724
Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUMMARY PRODUCT INFORMATION</td>
<td>3</td>
</tr>
<tr>
<td>INDICATIONS AND CLINICAL USE</td>
<td>3</td>
</tr>
<tr>
<td>CONTRAINDICATIONS</td>
<td>3</td>
</tr>
<tr>
<td>WARNINGS AND PRECAUTIONS</td>
<td>4</td>
</tr>
<tr>
<td>ADVERSE REACTIONS</td>
<td>6</td>
</tr>
<tr>
<td>DRUG INTERACTIONS</td>
<td>7</td>
</tr>
<tr>
<td>DOSAGE AND ADMINISTRATION</td>
<td>9</td>
</tr>
<tr>
<td>OVERDOSAGE</td>
<td>9</td>
</tr>
<tr>
<td>ACTION AND CLINICAL PHARMACOLOGY</td>
<td>10</td>
</tr>
<tr>
<td>STORAGE AND STABILITY</td>
<td>11</td>
</tr>
<tr>
<td>DOSAGE FORMS, COMPOSITION AND PACKAGING</td>
<td>11</td>
</tr>
</tbody>
</table>

PART II: SCIENTIFIC INFORMATION

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHARMACEUTICAL INFORMATION</td>
<td>12</td>
</tr>
<tr>
<td>DETAILED PHARMACOLOGY</td>
<td>13</td>
</tr>
<tr>
<td>TOXICOLOGY</td>
<td>18</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>20</td>
</tr>
</tbody>
</table>

PART III: CONSUMER INFORMATION

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>22</td>
</tr>
</tbody>
</table>
TEVA-CLONIDINE
(clonidine hydrochloride)

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form/ Strength</th>
<th>All Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Tablet / 0.025 mg</td>
<td>Colloidal silicon dioxide, dibasic calcium phosphate, lactose monohydrate (spray dried), magnesium stearate, pregelatinized starch and tablet coating containing: FD&amp;C Blue #2, hypromellose, polyethylene glycol, polyvinyl alcohol - partially hydrolyzed, talc and titanium dioxide.</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE
TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the relief of menopausal flushing in patients for whom hormonal replacement therapy is either unnecessary or not desirable.

Pediatrics (< 18 years of age):
Safety and effectiveness in children has not been established.

CONTRAINDICATIONS
TEVA-CLONIDINE (clonidine hydrochloride) is contraindicated in patients with the following:
- know hypersensitivity to the active substance or to any of the ingredients of the product. For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING section.
- severe bradyarrhythmia resulting from either sick sinus syndrome or atrioventricular block of 2nd or 3rd degree; patients with sinus node function impairment.
- rare hereditary conditions that may be incompatible with an excipient of the product (see DOSAGE FORMS, COMPOSITION AND PACKAGING sections).

This product contains 80.1 mg of lactose per maximum recommended daily dose. Patients with the rare hereditary conditions of galactose intolerance e.g. galactosaemia
should not take this medicine.

WARNINGS AND PRECAUTIONS

General

An abrupt withdrawal of higher doses of clonidine hydrochloride is followed in some cases by an excess of circulating catecholamines. Therefore, caution should be exercised in concomitant use of drugs which affect the metabolism, tissue uptake or pressor effects of these amines (monoamine oxidase inhibitors, tricyclic antidepressants and beta-blocking agents) (see DRUG INTERACTIONS section).

TEVA-CLONIDINE (clonidine hydrochloride 0.025 mg (blue tablets)) should not be confused with higher strength dosage forms containing the same active ingredient (clonidine hydrochloride 0.1 mg (white tablets) or 0.2 mg (orange tablets)) used for treating hypertension. Caution should however be exercised in patients receiving antihypertensive therapy because of the possibility of an additive effect.

Patients who engage in potentially hazardous activities such as operating machinery or driving should be warned of the possible sedative effect of clonidine hydrochloride (see WARNINGS AND PRECAUTIONS: Effects on ability to drive and use machines). Caution should be exercised in the concomitant administration of sedatives, tranquilizing drugs or alcohol (see DRUG INTERACTIONS).

Patients should be instructed not to discontinue therapy without consulting their physician (see DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustment section).

Carcinogenesis and Mutagenesis
See the TOXICOLOGY section.

Cardiovascular

Blood Pressure

Clonidine hydrochloride can have a hypotensive effect especially in high doses. In patients whose blood pressure decreases to an intolerable extent when taking TEVA-CLONIDINE, treatment should be discontinued.

An excessive rise in blood pressure following discontinuation of TEVA-CLONIDINE therapy can be reversed by intravenous phentolamine.

Because it can lower blood pressure at high doses, TEVA-CLONIDINE (clonidine hydrochloride) should be used with caution in patients with severe coronary insufficiency, recent myocardial infarction, cerebral vascular disease, or chronic renal failure. TEVA-CLONIDINE should be used with caution in patients with mild to moderate bradyarrhythmia such as low sinus
rhythm, with disorders of cerebral or peripheral perfusion, polyneuropathy, and constipation, patients with heart failure or severe coronary heart disease.

**Heart Rate**

Depending on the dose given, TEVA-CLONIDINE can lower the heart and pulse rate. In patients with diseases affecting the rhythmic and atrioventricular conduction system of the heart, arrhythmias have been observed after high doses.

**Heart Disease**

Patients with heart failure or severe coronary disease should be monitored particularly carefully when using TEVA-CLONIDINE.

**Other**

A few instances of a condition resembling Raynaud's phenomenon have been reported with the higher doses of clonidine as used in the therapy of hypertension. Caution should be observed if patients with Raynaud's disease or thromboangiitis obliterans are to be treated with TEVA-CLONIDINE.

**Ophthalmologic**

In several studies clonidine hydrochloride produced a dose-dependent increase in the incidence and severity of spontaneously occurring retinal degeneration in albino rats treated for six months or longer (see TOXICOLOGY). In view of this retinal degeneration, eye examinations were performed in 908 hypertensive patients prior to the start of clonidine hydrochloride therapy, who were then examined periodically thereafter. In 353 of these 908 patients, examinations were performed for periods of 24 months or longer. Except for the dryness of the eyes, no drug-related abnormal ophthalmologic findings were recorded and clonidine hydrochloride did not alter retinal function as shown by specialized tests such as the electroretinogram and macular dazzle.

Patients who wear contact lenses should be warned that treatment with TEVA-CLONIDINE may cause decreased lacrimation.

**Psychiatric**

Patients with a known history of depression should be carefully supervised while under treatment with clonidine as there have been occasional reports of further depressive episodes occurring in such patients.

**Renal**

Clonidine and its metabolites are extensively excreted with urine. As a result, TEVA-CLONIDINE should be used with caution in patients with renal insufficiency. Careful monitoring of blood pressure is required.

As with any drug excreted primarily in the urine, smaller doses of the drug are often effective in treating patients with a degree of renal failure. In patients exhibiting renal failure or insufficiency, periodic determination of the BUN is indicated. If, in the physician's opinion, a rising BUN is significant, the drug should be stopped.
Sexual Function/Reproduction

No clinical studies on the effect on human fertility have been conducted with clonidine. Non-clinical studies with clonidine indicate that it adversely affects fertility in female rats (see TOXICOLOGY).

Special Populations

Pregnant Women: There are no adequate and well-controlled studies in pregnant women. Thus, use of clonidine hydrochloride in pregnancy is not recommended. In case of accidental use of clonidine hydrochloride in pregnancy, careful monitoring of mother and child is recommended. There is no adequate experience regarding the long-term effects of prenatal exposure. Clonidine passes the placental barrier and may lower the heart rate of the foetus. Also in post partum a transient rise in blood pressure in the newborn cannot be excluded.

Non-clinical studies showed clonidine hydrochloride to have adverse effects with respect to reproductive toxicity at doses below the clinically administered dose (see TOXICOLOGY).

Nursing Women: Clonidine is excreted in human milk. However, there is insufficient information on the effect on newborns. The use of TEVA-CLONIDINE is therefore not recommended during breast feeding.

Pediatrics (<18 years of age): Safety and effectiveness in children has not been established.

Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. However, patients should be advised that they may experience undesirable effects such as dizziness, sedation and accommodation disorder during treatment with clonidine hydrochloride. Therefore, caution should be recommended when driving a car or operating machinery. If patients experience the above mentioned side effects they should avoid potentially hazardous tasks such as driving or operating machinery.

ADVERSE REACTIONS

Adverse Drug Reaction Overview

Most adverse reactions associated with the use of TEVA-CLONIDINE (clonidine hydrochloride) are mild and diminish with continued therapy.

Accumulated clinical and postmarketing data indicate provides some insight into adverse reactions. The information from this section is based on 22 clinical studies, which were published between 1968 and 1985. The studies comprised of 640 patients, which have been treated with clonidine hydrochloride. The following lists of adverse reactions have been noted with the use of clonidine hydrochloride.
Endocrine disorders:
gynaecomastia

Psychiatric disorders:
confusional state, delusional perception, depression, hallucination, libido decreased, nightmare, sleep disorder

Nervous system disorders:
dizziness, headache, paraesthesia, sedation
Eye disorder:
accommodation disorder, lacrimation decreased

Cardiac disorders:
atrioventricular block, bradyarrhythmia, sinus bradycardia

Vascular disorders:
orthostatic hypotension, Raynaud's phenomenon, reduction in blood pressure

Respiratory, thoracic and mediastinal disorders:
nasal dryness

Gastrointestinal disorders:
colonic pseudo-obstruction, constipation, dry mouth, nausea, salivary gland pain, vomiting, cramps, accelerated rate of dental caries

Skin and subcutaneous tissue disorders:
Alopecia, pruritus, rash, urticaria

Reproductive system and breast disorders:
erectile dysfunction

General disorders and administration site conditions:
fatigue, malaise, drowsiness, muscle or joint pain

Investigations:
blood glucose increased

**DRUG INTERACTIONS**

**Drug-Drug Interactions**

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction.
<table>
<thead>
<tr>
<th>Drug-Food Interactions</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Other anti-hypertensive agents such as diuretics, vasodilators, β blockers, calcium antagonists and ACE-inhibitors, but not α₁-blocking agents</strong></td>
<td>The reduction in blood pressure induced by clonidine can be further potentiated by concurrent administration.</td>
<td></td>
</tr>
<tr>
<td><strong>B-blockers and/or cardiac glycosides</strong></td>
<td>Concomitant use can further lower heart rate (bradycardia) or cause dysrhythmia (atrioventricular block) in isolated cases.</td>
<td></td>
</tr>
<tr>
<td><strong>Beta-receptor blocker</strong></td>
<td>It cannot be ruled out that concomitant administration will cause or potentiate peripheral vascular disorders.</td>
<td></td>
</tr>
<tr>
<td><strong>Tricyclic antidepressants or neuroleptics with alpha-receptor blocking properties</strong></td>
<td>The antihypertensive effect of clonidine may be reduced or abolished and orthostatic regulation disturbances may be provoked or aggravated by concomitant administration. Amitriptyline in combination with clonidine hydrochloride enhances the manifestation of corneal lesions in rats (see TOXICOLOGY).</td>
<td>If clonidine hydrochloride and tricyclic antidepressants are administered as concurrent therapy, an increase in the dosage of clonidine hydrochloride may be necessary.</td>
</tr>
<tr>
<td><strong>Substances with alpha₂ receptor blocking properties such as phentolamine</strong></td>
<td>May abolish the alpha₂-receptor mediated effects of clonidine in a dose-dependent manner.</td>
<td></td>
</tr>
<tr>
<td><strong>Sympathomimetic amines, indomethacin and possibly other non-steroidal anti-inflammatory agents</strong></td>
<td>May reduce the antihypertensive effects of clonidine hydrochloride. Substances which raise blood pressure or induce a Na⁺ and water retaining effect such as non steroidal anti-inflammatory agents can reduce the therapeutic effect of clonidine.</td>
<td>The patient should be carefully monitored to confirm that the desired effect is being obtained.</td>
</tr>
<tr>
<td><strong>Alcohol, barbiturates or other sedatives.</strong></td>
<td>Clonidine hydrochloride may enhance the CNS-depressive effects</td>
<td></td>
</tr>
<tr>
<td><strong>Drugs which affect the metabolism, tissue uptake or pressor effects of catecholamines (monoamine oxidase (MAO) inhibitors, tricyclic antidepressants and beta blocking agents, respectively).</strong></td>
<td>Withdrawal of clonidine hydrochloride may result in an excess of circulating catecholamines (see WARNINGS AND PRECAUTIONS).</td>
<td>Caution should be exercised in concomitant use of these drugs.</td>
</tr>
<tr>
<td><strong>Methylphenidate</strong></td>
<td>The concomitant use with clonidine has resulted in serious adverse reactions, including death, in children with attention-deficit/hyperactivity (ADHD).</td>
<td></td>
</tr>
</tbody>
</table>

**Drug-Food Interactions**

Interactions with food have not been established.
**Drug-Herb Interactions**
Interactions with herbs have not been established.

**Drug-Laboratory Test Interactions**
In rare cases, an increase in blood glucose has occurred in clinical studies.

**DOSAGE AND ADMINISTRATION**

**Recommended Dose and Dosage Adjustment**
The recommended dose for the treatment of menopausal flushing is 0.05 mg of TEVA-CLONIDINE (clonidine hydrochloride) twice daily. If after two to four weeks there has been no remission, the treatment should be discontinued and the patient reassessed.

Attempts should be made to discontinue treatment at three to six month intervals for patient re-evaluation of menopausal symptoms.

Following sudden discontinuation of clonidine hydrochloride after prolonged treatment with high doses, restlessness, palpitations, rapid rise in blood pressure, nervousness, tremor, headache or nausea have been reported. When discontinuing therapy with TEVA-CLONIDINE, the physician should reduce the dose gradually over 2-4 days.

**Missed Dose**
If a dose of TEVA-CLONIDINE is missed, patients should take the dose as soon as possible and then return to their normal schedule.

**Administration**
The tablets should be swallowed whole with water.

**OVERDOSAGE**

For management of a suspected drug overdose, contact your regional Poison Control Centre.

The signs and symptoms of clonidine hydrochloride overdosage are due to generalized sympathetic depression and include pupillary constriction, hypotension, hypothermia, bradycardia, lethargy, irritability, weakness, somnolence including coma, diminished or absent reflexes, vomiting and hypoventilation. With large overdoses, reversible cardiac conduction defects or arrhythmias, coma, respiratory depression including apnea, seizures and transient hypertension have been reported.

In a patient who ingested 100 mg clonidine hydrochloride, plasma clonidine levels were 60 ng/mL (one hour), 190 ng/mL (1.5 hours), 370 ng/mL (two hours) and 120 ng/mL (5.5 and 6.5 hours). This patient developed hypertension followed by hypotension, bradycardia, apnea, hallucinations, semicoma, and premature ventricular contractions. The patient fully recovered after intensive treatment.
ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

TEVA-CLONIDINE (clonidine hydrochloride) reduces the response of peripheral vessels to either vasoconstrictor or vasodilator stimuli. Clonidine hydrochloride, the active ingredient, is an α-adrenergic agonist which also has some α-adrenergic antagonist effects.

Clonidine hydrochloride therapy has been shown to reduce the frequency, severity, and duration of flushing attacks associated with the menopausal syndrome. There is a gradual onset of therapeutic response, and a gradual return of symptoms on interruption of treatment.

TEVA-CLONIDINE will not correct or relieve other menopausal changes that are due to hormonal deficiencies.

Clonidine stimulates alpha-adrenoreceptors in the brain stem, resulting in reduced sympathetic outflow from the central nervous system and a decrease in peripheral resistance, renal vascular resistance, heart rate, and blood pressure. Renal blood flow and glomerular filtration rate remain essentially unchanged.

Acute studies with clonidine hydrochloride in humans have demonstrated a moderate reduction (15%-20%) of cardiac output in the supine position with no change in the peripheral resistance, at a 45° tilt there is a smaller reduction in cardiac output and a decrease in peripheral resistance. During long-term therapy, cardiac output tends to return to controlled values, while peripheral resistance remains decreased.

Slowing of the pulse rate has been observed in most patients given clonidine, but the drug does not alter normal hemodynamic response to exercise.

Other studies in patients have provided evidence of a reduction in plasma renin activity and in the excretion of aldosterone and catecholamines, but the exact relationship of these pharmacologic actions to the antihypertensive effect has not been fully elucidated.

Clonidine acutely stimulates growth hormone release in both children and adults, but does not produce a chronic elevation of growth hormone with long-term use.

Pharmacodynamics

Clonidine hydrochloride acts relatively rapidly. The patient's blood pressure declines within 30 to 60 minutes after an oral dose, the maximum decrease occurring within 2 to 4 hours.

In humans, the blood pressure reduction due to higher doses of clonidine does not cause significant alterations in renal blood flow in the supine position. In the erect position, a consistent decrease in renal vascular resistance is seen.
Absorption: The plasma level of clonidine hydrochloride peaks in approximately 3 to 5 hours. In humans, a significant plasma level (0.20 μg% of clonidine) can be detected one hour after oral administration of a single dose of 390 μg.

Distribution: Clonidine is 30-40% bound to plasma proteins.

Metabolism: About 50% of the absorbed dose is metabolized in the liver. Four different metabolites have been detected in humans.

Excretion: Following oral administration about 40-60% of the absorbed dose is recovered in the urine as unchanged drug in 24 hours. Clonidine is excreted in human milk (see WARNINGS AND PRECAUTIONS, Special Populations, Nursing Women). However, there is insufficient information on the effect of newborns.

The terminal elimination half-life ranges from 5 to 25.5 hours, but the half-life increases up to 41 hours in patients with severe impairment of renal function. In humans, 65% of the orally administered drug is excreted in the urine, and an estimated 22% in the faeces.

STORAGE AND STABILITY
TEVA-CLONIDINE tablets should be stored at controlled room temperature (15°C -30°C). Protect from moisture.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Dosage Forms
0.025 mg tablet: Blue, round, biconvex, film-coated tablets, engraved N on one side and plain on the other side.

Composition
The TEVA-CLONIDINE (clonidine hydrochloride) tablet core contains clonidine hydrochloride and the following non-medicinal ingredients: colloidal silicon dioxide, dibasic calcium phosphate, lactose monohydrate (spray dried), magnesium stearate and pregelatinized starch.

The TEVA-CLONIDINE tablet coating contains: FD&C Blue #2, hypromellose, polyethylene glycol, polyvinyl alcohol - partially hydrolyzed, talc and titanium dioxide.

Packaging
TEVA-CLONIDINE 0.025 mg tablets are supplied in bottles of 100 and 500 tablets.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

<table>
<thead>
<tr>
<th>Proper Name</th>
<th>clonidine hydrochloride</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical Name</td>
<td>2-[(2,6-Dichlorophenyl)imino]imidazolidine monohydrochloride</td>
</tr>
<tr>
<td>Structural Formula</td>
<td><img src="image" alt="Structural formula" /></td>
</tr>
<tr>
<td>Molecular Formula</td>
<td>C₉H₉N₃Cl₂•HCl</td>
</tr>
<tr>
<td>Molecular Mass</td>
<td>266.56 g/mol</td>
</tr>
</tbody>
</table>

Physicochemical properties: Clonidine hydrochloride occurs as white crystalline powder. It is soluble in water, methanol, and ethanol; slightly soluble in chloroform. The pH of a 5% aqueous solution lies between 4 and 5.
CLINICAL STUDIES

COMPARATIVE BIOAVAILABILITY STUDY

An evaluation of the comparative bioavailability between Teva-Clonidine 0.025 mg Tablets (Teva Canada Limited, Canada) and Dixarit® 0.025 mg Tablets (Boehringer Ingelheim Ltd., Canada) after a single-dose in 24 healthy male and female volunteers under fasting conditions. A summary of the results is presented below.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Test*</th>
<th>Reference †</th>
<th>% Ratio of Geometric Means</th>
<th>90% Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUCₜ (pg.h/ml)</td>
<td>2768.38 2848.83 (24)</td>
<td>2691.99 2779.65 (25)</td>
<td>102.84</td>
<td>98.60 - 107.26</td>
</tr>
<tr>
<td>AUCᵢ (pg.h/ml)</td>
<td>2944.42 3052.03 (27)</td>
<td>2863.63 2968.03 (27)</td>
<td>102.82</td>
<td>98.53 - 107.30</td>
</tr>
<tr>
<td>Cₚₘₐₓ (pg/ml)</td>
<td>186.14 188.96 (18)</td>
<td>185.64 190.21 (24)</td>
<td>100.27</td>
<td>96.47 - 104.22</td>
</tr>
<tr>
<td>Tₘₚₓ § (h)</td>
<td>2.12 (37)</td>
<td>2.03 (37)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T½ § (h)</td>
<td>11.39 (27)</td>
<td>11.18 (21)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Teva-Clonidine 0.025 mg Tablets (Teva Canada Limited, Canada)  
† Dixarit® 0.025 mg Tablets (Boehringer Ingelheim (Canada) Ltd., Canada)  
‡ Expressed as the arithmetic mean (CV%) only

DETAILED PHARMACOLOGY

Pharmacokinetics

Clonidine is well absorbed from the intestine in all species examined. In the dog, plasma levels can be detected one hour after administration of an oral dose of 0.52 mg/kg, and maximum plasma levels are reached after 4-8 hours. In man, a significant plasma level (0.20 µg% of clonidine) can be detected one hour after oral administration of a single dose of 390 µg. Since clonidine is approximately 50% bound, this reflects an actual free plasma level. Peak plasma levels in man and monkey occur after three hours and decline with a half-life of twenty hours. Elimination decreases after twenty-four hours and is completed only after five days.
In rats, clonidine hydrochloride tissue levels are distinctly above blood levels. They show similar distribution patterns over heart, liver, lung, spleen, testes, brain, adrenal gland, fat and muscle after either oral or i.v. administration. The highest concentration of clonidine after oral administration is found in the kidneys and the gastrointestinal tract, but only very small amounts can be detected in these organs forty-eight hours after administration. There is a high concentration of clonidine in the lacrimal and parotid glands (40 times higher than the blood level).

The cerebrospinal fluid contains only half the plasma concentration of clonidine, which might be interpreted as an expression of affinity for brain tissue. The overall brain distribution suggests a greater affinity for noradrenergic than for other aminergic cell systems.

An enterohepatic circulation of clonidine has been described in the rat. Up to 24% of an oral dose is excreted in the bile, within the first 24-48 hours.

A large proportion (90-95%) of the given dose is metabolized in dogs and monkeys, whereas in humans clonidine is less extensively metabolized. In dogs, after 48 hours up to 80% of the administered radioactive clonidine is excreted in the urine, and up to 18% in the feces. In man, 65% of the orally administered drug is excreted in the urine and an estimated 22% in the feces. Fifty-eight percent of the activity in human urine at 24 hours, and 44% at 48 hours is unchanged clonidine. Four different metabolites have been detected in man.

**Effects on the Cardiovascular System**

Clonidine has two opposing actions on the cardiovascular system. As an alpha-sympathomimetic it constricts blood vessels but, as it seems devoid of beta-stimulant action, it does not directly influence the heart. The very potent inhibitory action on central spontaneous sympathetic activity tends to reduce the peripheral resistance and to decrease cardiac output. In addition, a vagal component appears to be involved, since phentolamine or reserpine abolish the effect on blood pressure but only decrease the bradycardia produced by clonidine, while atropine decreases the hypotension and bradycardia.

Clonidine has neither a ganglionic nor a postganglionic blocking action; it is free of alpha- and beta-adrenergic blocking actions; it does not act on vagal receptors, and it does not interfere with the catecholamine content of the various tissues.

Intravenous doses (1-100 µg/kg) of clonidine given to animals of different species, either intact or in various experimental preparations, exert a biphasic cardiovascular effect: (a) an initial very brief rise of the blood pressure is followed by (b) a sustained fall.

a) The brief vasopressor effect shows the following characteristics: (1) it is not prevented by pre-treatment with reserpine; (2) it is abolished by pretreatment with phentolamine; (3) it is reduced by cocaine; (4) it is still elicited in the spinal, decerebrated, decapitated, pithed, immunosympathectomized, bivagotomized, stellate ganglionectomized and debuffered animal; and (5) it is accompanied by bradycardia.
In addition clonidine causes direct vasoconstriction in isolated organs. In experiments with isolated smooth muscles of rabbits (non-pregnant uterus, small intestine and blood vessels of the ear), clonidine appears to compete with adrenaline and causes an adrenaline-like effect.

Contrary to the initial vasopressor effect of guanethidine and bretylium, clonidine does not interfere with the synthesis, storage, or release of catecholamines from the nerve endings. Clonidine is less depressant than guanethidine upon reflex blood pressure responses, as shown by the conservation of the normal diving reflex in ducks and by the absence of effect on the blood pressure response to vertical tilting in dogs. However, clonidine markedly enhances the pressure-induced reflex bradycardia in dogs (total heart-lung bypass); this effect is abolished by stellate ganglionectomy and bivagotomy.

Bradycardia is seen with 5 µg/kg i.v. in experimental animals, but total denervation of the heart abolishes any bradycardiac response to i.v. doses as high as 1 mg/kg. In very high doses it has been shown, however, that clonidine is depressant directly upon the myocardium.

b) The long-lasting, slow-recovering depressor phase of clonidine is clearly dose-dependent and shows the following characteristics:

(1) it is inhibited by pretreatment with reserpine or phentolamine; (2) it is absent in the spinal, pithed or decapitated animal; (3) it is elicited by injection of minute quantities (even 1/100 of the intravenous dose) administered directly into the central nervous system (intracisternal, intrahypothalamic or intraventricular injection, or infusion into the vertebral arteries) and (4) it is also accompanied by bradycardia which persists throughout the entire blood pressure response to clonidine.

Clonidine reduces the cardiac output in dogs and rabbits. Apparently, this is not due to a direct negative inotropic effect upon the cardiac muscle or to a local action on the pacemaker region, nor does it arise as a reflex response to a change in blood pressure. It is apparently due to a reduction in the sympathetic drive to the heart or to the systemic venodilatation caused by the drug. No change is seen in this cardiac response after vagotomy.

Clonidine decreases the neuronal traffic in the sympathetic nervous system or at least changes the pattern of sympathetic discharges, inhibiting centrally the bulbar sympathetic cardioaccelerator and vasoconstrictor mechanisms. In different animal species the impulse traffic in the renal, phrenic, cervical, splanchnic, and cardiac sympathetic nerves (pre- or postganglionic) rapidly decreases after clonidine and finally disappears. Clonidine does not reduce the discharges in all the sympathetic nerves to the same extent, the cardiac nerve being less affected. This effect is dose-dependent, lasts as long as the hypotension and the bradycardia and is not influenced by vagotomy nor by suppression of afferent input from the peripheral chemoreceptors.

The depression of the sympathetic activity is more effective on the spontaneous discharges than on reflexly or centrally evoked discharges, especially if submaximal or supramaximal stimulation at low frequencies is used. An adrenergic block is not the reason for the decrease in
the sympathetic tone since low doses of clonidine potentiate and prolong the blood pressure
effect of adrenaline and prolong the responses to noradrenaline.

The biphasic change in arterial blood pressure is accompanied by a corresponding sharp increase
and then a fall in total peripheral resistance. The significant reduction in the total peripheral
resistance obtained in unanaesthetized rabbits by single intravenous injections of clonidine is
unaffected even when the effects of the autonomic nervous system are blocked by pretreatment
with phenoxybenzamine, propranolol and atropine. This indicates that clonidine may have a
direct peripheral vasodilator action in addition to its effect on the CNS and its peripheral
sympathomimetic effect, especially when the level of resting sympathetic activity is low. In dogs
there is a decreased skin and skeletal muscle blood flow during the transient pressor phase, but
the coronary blood flow is increased, indicating either a lesser degree of vasoconstriction relative
to that in other vascular fields, or vasodilatation.

The depressor phase usually shows an increase in the circulatory capacity. There is a
responding change in the regional distribution of blood in the peripheral circulation; the
vascular resistance in the cutaneous and skeletal beds decreases, whereas the cerebral, pulmonary
renal and splanchnic vascular fields show variable responses. A fall in the calculated coronary
vascular resistance has been demonstrated in the dog heart-lung bypass preparation with separate
coronary and systemic perfused circulation, even when the heart rate was maintained constant.

Effects on Vascular Reactivity
Administration of oral clonidine to cats at a dose of 10 µg/kg/day for 4 weeks or 20 µg/kg/day
for seven days resulted in a reduction in vascular response to either vasoconstrictor or vasodilator
stimuli. The vasoactive drugs administered under general anesthesia were epinephrine,
norepinephrine, isoprenaline and angiotensin.

Reduced vascular reactivity to angiotensin, norepinephrine and vasopresin administered
intravenously was observed in conscious rats. These effects were also seen after single
intramuscular doses of 1, 3, or 10 µg/kg of clonidine either before or after ganglion blockade as
well as after seven days of intramuscular administration of 20 µg/kg of clonidine.

Effects on the Kidney, Renal Hemodynamics and Sodium Balance
In acute studies clonidine given intravenously or by infusion into the renal artery diminishes the
renal blood flow and reduces the excretion of sodium in dogs. However, the intravenous or
intraperitoneal administration of clonidine to rats enhances the diuresis and produces a dose-
dependent increase in the excretion of inorganic ions, their relative composition being quite
uniform.

In man, the blood pressure reduction due to higher doses of clonidine does not cause significant
alterations in renal blood flow in the supine position. In the erect position, a consistent decrease
in renal vascular resistance is seen.

In animals, acute administration of the drug causes a dose-related increase in renal vascular
resistance without any change in glomerular filtration rate. There is correlation between these
effects and increased tubular reabsorption of sodium.
Clinically there may be some sodium retention and slight weight gain during the initial three to four days of clonidine hydrochloride therapy for hypertension. Thereafter, the sodium is re-excreted and weight goes down during continued administration of the drug. These transient changes in sodium balance are rarely of clinical significance and are not seen at all if clonidine is given concomitantly with a diuretic.

**Effects on the Central Nervous System**
In acute experiments a dose-dependent sedative action has been demonstrated in cats and dogs receiving i.v. clonidine. In rats there is a reduction of exploratory behaviour and inhibition of pain-induced aggression in doses smaller than or equal to those effective in producing hypotension.

Mice have shown exophthalmos, horripilation and intense tremors at 1-5 mg/kg and marked aggressivity at 10 mg/kg, followed by sedation and reduction of spontaneous mobility. The conditioned avoidance behaviour of guinea pigs and rats is inhibited by clonidine, and the young chicken suffers a loss of the righting reflex. Very small doses (0.02 µg/kg) induce sleep in young chickens. The depth and the duration of sleep (either behavioural or barbital-or chloral-induced) are potentiated by clonidine in rat, mouse and cat. Given i.v., clonidine produces in rabbits a typical resting EEG. The cat EEG shows synchronization, slower waves and a decrease of faster waves.

In mice the drug has an analgesic action, as these animals do not take up their usual defence and escape reaction. A local anaesthetic action has been observed at very high doses. Clonidine closely resembles the typical local anaesthetic procaine, as shown by electrophysiological studies of intracellular action potentiates and membrane resistance and firing threshold of the crayfish stretch receptor. The local anaesthetic effect of clonidine appears to be much more potent than the effect produced by tetracaine on the rabbit cornea.

**Effect on Salivation and Gastric Secretion**
Clonidine greatly reduces the conditioned salivation in dogs, but has no effect upon the salivation produced either by pilocarpine or by stimulation of the chorda tympani. The most likely action of the drug is upon central nervous centers controlling salivation, and not by a peripheral effect. Given intravenously, clonidine inhibits the gastric secretion and reduces its acidity in rats, thus giving protection against stress- and reserpine-induced ulcers and gastric haemorrhage, but it is ineffective against histamine- and serotonin-provoked ulcers.

**Metabolic effects**

Intravenous administration of clonidine increases the pool, life and turnover of body glucose in the rat, and decreases glucose oxidation. There is no change in muscle glycogen, but liver glycogen is lowered. A dose-dependent hyperglycemia has been described in cats receiving clonidine (infusion of 10 µg/kg. into the vertebral arteries provokes a 30% higher level than control), but this effect is less marked in adrenalectomized animals.

Rabbits show hyperglycemia with very high doses only. Normal and fasting rats also show increased plasma glucose levels after clonidine given by different routes. Clonidine does not
affect the plasma level of free fatty acids, but with very high doses has increased the plasma renin level in rats.

Although single large doses of clonidine impair glucose handling, presumably because of the transient adrenergic effects described above, no effects on glucose metabolism are seen during the long term clinical use of the drug.

**TOXICOLOGY**

**Acute Toxicity**
The oral LD$_{50}$ of clonidine in rats was 465 mg/kg, and in mice 206 mg/kg.

The LD$_{50}$ in 24 hours when given intravenously to mice is 17.6 mg/kg; the LD$_{50}$ during a 14-day observation period following a single oral dose is over 30 mg/kg in dogs.

**Long Term Toxicity**

Subacute (12-13 weeks) and chronic (26-78 weeks) toxicity studies have ruled out any increased morbidity or mortality due to a cumulative effect or possible organ damage. No abnormality has been recorded in blood, urine or internal organs after subacute dosages. In rats, there is a clear dose-related lag in weight gain, and sedation with a brief hyperactive phase immediately following the administration of the drug. Dogs show a dose-related restriction of growth; female dogs in subacute i.v. toxicity studies were anovulatory with high daily doses (0.5 mg/kg.). Glycosuria has been found in rabbits receiving 1 mg/kg daily for 30 days. No significant drug induced pathological or histological change in the circulatory and parenchymatous organs of the rat or in the endocrine organs of mice and rabbits has been observed.

**Ophthalmological Toxicity**

In several studies, clonidine hydrochloride produced a dose-dependent increase in the incidence and severity of spontaneously occurring retinal degeneration in albino rats treated for 6 months or longer. Tissue distribution studies in dogs and monkeys revealed that clonidine hydrochloride was concentrated in the choroid of the eye.

In rats, clonidine hydrochloride in combination with amitriptyline produced corneal lesions within 5 days.

**Tolerance**

Tolerance to clonidine has not been demonstrated in either dogs or in rats, as shown by two exactly measurable parameters (mydriasis and bradycardia).

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

In a 132-week (fixed concentration) dietary administration study in rats, clonidine hydrochloride administered at 32 to 46 times the maximum recommended daily human dose was unassociated with evidence of carcinogenic potential. Fertility of male or female rats was unaffected by
clonidine hydrochloride doses as high as 150 µg/kg or about 3 times the maximum recommended daily human dose (MRDHD). Fertility of female rats did, however, appear to be affected (in another experiment) at dose levels of 500 to 2000 µg/kg or 10 to 40 times the MRDHD.

**Teratogenicity**

Reproduction studies performed in rabbits of doses up to approximately 3 times the maximum recommended daily human dose (MRDHD) of clonidine hydrochloride have revealed no evidence of teratogenic or embryotoxic potential in rabbits. In rats, however, doses as low as 1/3 the MRDHD were associated with increased resorptions in a study in which dams were treated continuously from 2 months prior to mating. Increased resorptions were not associated with treatment at the same or at higher dose levels (up to 3 times the MRDHD) when dams were treated on days 6-15 of gestation. Increased resorptions were observed at much higher levels (40 times the MRDHD) in rats and mice treated on days 1-14 of gestation (lowest dose employed in that study was 500 µg/kg).
REFERENCES


16. Edington RF, Chagnon JP. Clonidine (Dixarit) for menopausal flushing. Can Med Assoc J. 1980;123:23-6,


27. A Single-Dose, Comparative Bioavailability Study of Two Formulations of Clonidine Hydrochloride 0.025 mg Tablets Under Fasting Conditions. Data on file at Teva Canada Limited.
PART III: CONSUMER INFORMATION
Pr. TEVA-CLONIDINE (clonidine hydrochloride) Tablet

This leaflet is part III of a three-part "Product Monograph" published when TEVA-CLONIDINE was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about TEVA-CLONIDINE. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:
TEVA-CLONIDINE Tablets are used to provide relief from hot flushes that may occur in women at menopause (change of life).

What it does:
TEVA-CLONIDINE Tablets helps reduce the frequency, severity and duration of menopausal flushing (due to decreased estrogen levels).

When it should not be used:
Do not take this medicine if:
- You are allergic to clonidine hydrochloride or any other ingredients in TEVA-CLONIDINE or have a rare hereditary problem of galactose intolerance or the Lapp lactose deficiency. TEVA-CLONIDINE contains lactose.
- You have a severe slow heart rate; TEVA-CLONIDINE can lower the heart and pulse rate.

What the medicinal ingredient is:
clonidine hydrochloride.

What the nonmedicinal ingredients are:
The TEVA-CLONIDINE (clonidine hydrochloride) tablet core contains the following inactive ingredients: colloidal silicon dioxide, dibasic calcium phosphate, lactose monohydrate (spray dried), magnesium stearate and pregelatinized starch.

The TEVA-CLONIDINE tablet coating contains: FD&C Blue #2, hypromellose, polyethylene glycol, polyvinyl alcohol - partially hydrolyzed, talc and titanium dioxide.

What dosage forms it comes in:
TEVA-CLONIDINE is available in tablets. Each tablet contains 0.025 mg of clonidine hydrochloride.

WARNINGS AND PRECAUTIONS

BEFORE you use TEVA-CLONIDINE talk to your doctor or pharmacist about any health conditions or problems you may have, including if you:
- have low blood pressure;
- have a slow heart rate, or heart failure, or irregular heart rate, or a recent heart attack;
- have or have had a stroke;
- have poor blood circulation to hands and feet such as Raynaud's syndrome;
- are suffering from constipation;
- have kidney disease;
- have eye problems such as dry eye or wear contact lenses;
- have or have had depression;
- are pregnant or planning to become pregnant;
- are breast-feeding.

TEVA-CLONIDINE is not to be used in patients under 18 years of age.

TEVA-CLONIDINE may cause sleepiness, dizziness and fainting. Do not drive or operate machinery until you know how the drug affects you.

INTERACTIONS WITH THIS MEDICATION

Tell your doctor or pharmacist all the medicines you are taking including all prescription, non-prescription and natural health products, particularly if you are taking the following medicines:
- drugs that contain clonidine
- drugs that lower blood pressure such as water pills, betablockers, vasodilators, calcium antagonists, ACE-inhibitors
- drugs that slow the heart rate
- drugs for depression and MAO inhibitors
- alpha receptor blockers such as phentolamine
- methylphenidate
- indomethacin and other non-steroidal anti-inflammatory agents
- barbiturates or other sedatives, including alcohol

PROPER USE OF THIS MEDICATION

Follow your doctor's instructions about when and how to take your medicine and always read the label.

Usual dose:
0.05 mg (two 0.025 mg tablets) twice a day. The tablets should be swallowed whole with water.

Do not stop taking TEVA-CLONIDINE without talking to your doctor since
IMPORTANT: PLEASE READ

stopping TEVA-CLONIDINE suddenly may cause a severe withdrawal reaction, which in rare cases can cause death.

Overdose:

If you take more TEVA-CLONIDINE tablets than you should or in case of drug overdose, contact your doctor or a poison control centre or go to the emergency room of the hospital near you.

Missed Dose:

If you forget to take a dose take one as soon as you remember, then carry on as before.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Side effects may include: dry mouth, dizziness, tiredness, headache, nausea, vomiting, constipation, feeling weak (malaise), sleepiness, drowsiness and erectile dysfunction (trouble getting or keeping an erection), itchiness, rash, hive, hair loss.

If you experience any of these effects or any other effects not mentioned above and they continue or become troublesome, talk to your doctor or pharmacist.

TEVA-CLONIDINE can cause abnormal blood test results. TEVA-CLONIDINE may also increase blood sugar, you may need to test your blood sugar more often.

<table>
<thead>
<tr>
<th>Serious Side Effects, How Often They Happen and What to Do About Them</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symptom/effect</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Common</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Uncommon</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

This is not a complete list of side effects. For any unexpected effects while taking TEVA-CLONIDINE, contact your doctor or pharmacist.

HOW TO STORE IT

The tablets should not be taken after the expiry date which is printed on the label.

TEVA-CLONIDINE Tablets should be stored at room temperature (15°C - 30°C). Protect from moisture.

Keep this medicine out of the sight and reach of children.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to: Canada Vigilance Program
    Health Canada
    Postal Locator 0701E
    Ottawa, ON K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.
NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found by contacting Teva Canada Limited at: 1-800-268-4127 ext. 1255005 (English) or 1-877-777-9117 (French) or druginfo@tevacanada.com

This leaflet was prepared by:
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada, M1B 2K9

Last revised: February 6, 2014